NL300847I2 - - Google Patents

Download PDF

Info

Publication number
NL300847I2
NL300847I2 NL300847C NL300847C NL300847I2 NL 300847 I2 NL300847 I2 NL 300847I2 NL 300847 C NL300847 C NL 300847C NL 300847 C NL300847 C NL 300847C NL 300847 I2 NL300847 I2 NL 300847I2
Authority
NL
Netherlands
Application number
NL300847C
Original Assignee
Astra Zeneca Holding France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300847(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France filed Critical Astra Zeneca Holding France
Publication of NL300847I2 publication Critical patent/NL300847I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NL300847C 2002-01-28 2016-12-08 NL300847I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
NL300847I2 true NL300847I2 (nl) 2017-01-03

Family

ID=27619669

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300847C NL300847I2 (nl) 2002-01-28 2016-12-08

Country Status (45)

Country Link
US (4) US7612087B2 (nl)
EP (2) EP1480644B1 (nl)
JP (1) JP4472346B2 (nl)
KR (1) KR100979079B1 (nl)
CN (3) CN101406471A (nl)
AR (2) AR038234A1 (nl)
AT (1) ATE484281T1 (nl)
AU (1) AU2003214335B2 (nl)
BE (1) BE2016C069I2 (nl)
BR (1) BRPI0307267B8 (nl)
CA (1) CA2474043C (nl)
CL (1) CL2011000009A1 (nl)
CO (1) CO5601014A2 (nl)
CR (2) CR7387A (nl)
CY (3) CY1111061T1 (nl)
DE (1) DE60334527D1 (nl)
DK (2) DK2279737T3 (nl)
EA (1) EA007220B1 (nl)
EC (1) ECSP045193A (nl)
ES (2) ES2356813T3 (nl)
FR (1) FR2835186B1 (nl)
HK (2) HK1077205A1 (nl)
HR (1) HRP20040686B1 (nl)
HU (1) HUS1600055I1 (nl)
IL (1) IL163167A (nl)
JO (1) JO2646B1 (nl)
LT (1) LTC1480644I2 (nl)
MA (1) MA26351A1 (nl)
MX (1) MXPA04006621A (nl)
MY (1) MY140638A (nl)
NL (1) NL300847I2 (nl)
NO (2) NO335195B1 (nl)
NZ (1) NZ533936A (nl)
OA (1) OA12761A (nl)
PE (1) PE20030969A1 (nl)
PL (1) PL220725B1 (nl)
PT (2) PT2279737E (nl)
RS (1) RS52137B (nl)
SI (2) SI1480644T1 (nl)
TN (1) TNSN04137A1 (nl)
TW (1) TWI293071B (nl)
UA (1) UA80271C2 (nl)
UY (1) UY27626A1 (nl)
WO (1) WO2003063864A2 (nl)
ZA (1) ZA200405607B (nl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
CN102988362B (zh) * 2005-12-07 2014-11-05 巴斯利尔药物股份公司 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
CN101589047A (zh) * 2006-10-23 2009-11-25 Irm责任有限公司 组织蛋白酶类抑制剂
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
CA2712783C (en) * 2008-01-18 2013-03-19 Timothy A. Blizzard Beta-lactamase inhibitors
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
ES2408159T3 (es) * 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
ES2789177T3 (es) 2010-08-10 2020-10-26 Melinta Therapeutics Inc Derivados de éster del ácido borónico cíclicos, procedimiento para la preparación y usos terapéuticos de los mismos
US8772490B2 (en) * 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
DK2657234T3 (da) * 2010-12-22 2017-02-20 Meiji Seika Pharma Co Ltd Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf
SG195289A1 (en) 2011-06-17 2013-12-30 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
DK2748165T3 (en) * 2011-08-27 2016-12-19 Wockhardt Ltd 1,6-diazabicyclo [3,2,1] octane-7-ON DERIVATIVES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
ES2640520T3 (es) * 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
CN104334555A (zh) 2012-03-30 2015-02-04 丘比斯特药物股份有限公司 异噁唑β-内酰胺酶抑制剂
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3360877B1 (en) * 2012-08-25 2021-02-17 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US10000491B2 (en) 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
EP3613740A1 (en) 2013-10-08 2020-02-26 Meiji Seika Pharma Co., Ltd. Preparation of a diazabicyclooctane derivative
US20170065566A1 (en) * 2014-02-20 2017-03-09 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
MX2017006383A (es) 2014-11-17 2017-08-21 Entasis Therapeutics Ltd Terapia de combinacion para el tratamiento de infecciones bacterianas resistentes.
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
CN107001366B (zh) 2014-12-05 2020-08-28 明治制果药业株式会社 二氮杂二环辛烷衍生物的结晶以及稳定的冻干制剂的制备方法
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2016257338B2 (en) * 2015-05-07 2020-03-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017045510A1 (zh) * 2015-09-16 2017-03-23 山东轩竹医药科技有限公司 β-内酰胺酶抑制剂及其用途
KR20180051559A (ko) 2015-10-02 2018-05-16 주식회사 레고켐 바이오사이언스 베타-락타마제의 억제용 조성물 및 억제 방법
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
CA3036557A1 (en) 2016-09-16 2018-03-22 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
RU2019124705A (ru) 2017-02-06 2021-02-05 Мутабилис Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
MX2019013291A (es) 2017-05-08 2020-01-15 Entasis Therapeutics Inc Compuestos y metodos para tratar infecciones bacterianas.
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
CN115151544A (zh) * 2020-09-01 2022-10-04 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
DK0724587T3 (da) 1993-09-29 2003-01-06 Nabi Nukleosider og nukleotider med forstørrede ringe
AU699465B2 (en) * 1993-12-29 1998-12-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
ES2205072T3 (es) * 1996-01-03 2004-05-01 Smithkline Beecham Plc Derivados carbamoiloxi de mutilina y su uso como agentes antibacterianos.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
AU5265599A (en) 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
IL143409A0 (en) 1998-12-18 2002-04-21 Schering Corp Farnesyl protein transferase inhibitors
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
EP1408970B1 (en) 2001-02-22 2007-05-09 School Of Pharmacy, University Of London Indolines and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
NO20043587L (no) 2004-08-27
CA2474043C (fr) 2011-08-02
BRPI0307267B1 (pt) 2016-02-10
US7612087B2 (en) 2009-11-03
TWI293071B (en) 2008-02-01
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
BRPI0307267B8 (pt) 2021-05-25
LTC1480644I2 (lt) 2018-09-10
IL163167A (en) 2010-04-15
NO2016024I1 (no) 2016-12-15
ZA200405607B (en) 2005-09-28
US20100048528A1 (en) 2010-02-25
CN1655781A (zh) 2005-08-17
CN1994301A (zh) 2007-07-11
CN101406471A (zh) 2009-04-15
LTPA2016037I1 (lt) 2017-01-10
MA26351A1 (fr) 2004-10-01
CY1114417T1 (el) 2016-08-31
FR2835186B1 (fr) 2006-10-20
US20090215747A1 (en) 2009-08-27
NZ533936A (en) 2007-05-31
KR20040081473A (ko) 2004-09-21
EP2279737A1 (fr) 2011-02-02
JP4472346B2 (ja) 2010-06-02
HK1105864A1 (en) 2008-02-29
UA80271C2 (uk) 2007-09-10
PL220725B1 (pl) 2015-12-31
CA2474043A1 (fr) 2003-08-07
CN100563653C (zh) 2009-12-02
YU65804A (sh) 2006-08-17
MXPA04006621A (es) 2004-10-04
WO2003063864A3 (fr) 2004-03-11
AR038234A1 (es) 2005-01-05
ATE484281T1 (de) 2010-10-15
ES2356813T3 (es) 2011-04-13
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
CR7387A (es) 2010-10-25
HK1077205A1 (en) 2006-02-10
TNSN04137A1 (fr) 2007-03-12
WO2003063864A2 (fr) 2003-08-07
PL371601A1 (en) 2005-06-27
BE2016C069I2 (nl) 2022-05-17
CO5601014A2 (es) 2006-01-31
RS52137B (en) 2012-08-31
PT2279737E (pt) 2013-02-01
NO335195B1 (no) 2014-10-20
DK2279737T3 (da) 2013-02-11
ES2401855T3 (es) 2013-04-25
US20050020572A1 (en) 2005-01-27
CY2016042I2 (el) 2017-03-15
JP2005523897A (ja) 2005-08-11
DE60334527D1 (de) 2010-11-25
CY1111061T1 (el) 2015-06-11
CN100482225C (zh) 2009-04-29
CL2011000009A1 (es) 2011-03-25
HUS1600055I1 (hu) 2017-01-30
PT1480644E (pt) 2011-01-17
EA007220B1 (ru) 2006-08-25
HRP20040686A2 (en) 2004-12-31
ECSP045193A (es) 2004-08-27
US20110245254A1 (en) 2011-10-06
FR2835186A1 (fr) 2003-08-01
EA200400981A1 (ru) 2005-02-24
CY2016042I1 (el) 2017-03-15
AU2003214335B2 (en) 2007-04-05
EP2279737B1 (fr) 2012-10-31
BR0307267A (pt) 2004-12-07
UY27626A1 (es) 2003-08-29
MY140638A (en) 2010-01-15
EP1480644B1 (fr) 2010-10-13
SI1480644T1 (sl) 2011-03-31
JO2646B1 (en) 2012-06-17
KR100979079B1 (ko) 2010-08-31
HRP20040686B1 (hr) 2013-02-28
AR100790A2 (es) 2016-11-02
SI2279737T1 (sl) 2013-07-31
NO2016024I2 (no) 2016-12-15
OA12761A (fr) 2006-07-04
DK1480644T3 (da) 2011-01-24

Similar Documents

Publication Publication Date Title
BE2019C547I2 (nl)
BE2019C510I2 (nl)
BE2018C021I2 (nl)
BE2017C049I2 (nl)
BE2017C005I2 (nl)
NL300847I2 (nl)
BE2016C040I2 (nl)
BE2016C013I2 (nl)
BE2018C018I2 (nl)
BE2016C002I2 (nl)
BE2015C078I2 (nl)
BE2015C017I2 (nl)
BE2014C053I2 (nl)
BE2014C051I2 (nl)
BE2014C041I2 (nl)
BE2014C030I2 (nl)
BE2014C016I2 (nl)
BE2014C015I2 (nl)
BE2013C063I2 (nl)
BE2013C039I2 (nl)
BE2011C038I2 (nl)
JP2003193999A5 (nl)
JP2003216190A5 (nl)
BRPI0302144B1 (nl)
JP2003178163A5 (nl)